AxoGen, Inc. (NASDAQ:AXGN) has earned an average rating of “Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $14.38.

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of AxoGen in a research report on Thursday, June 29th. They set an “overweight” rating and a $18.00 price objective for the company. ValuEngine upgraded shares of AxoGen from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Wedbush restated an “outperform” rating and set a $14.00 price objective (down from $17.00) on shares of AxoGen in a research report on Friday, May 19th.

A number of hedge funds and other institutional investors have recently made changes to their positions in AXGN. SG Americas Securities LLC bought a new position in shares of AxoGen during the first quarter valued at $150,000. Campbell & CO Investment Adviser LLC raised its position in shares of AxoGen by 3.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 11,055 shares of the medical equipment provider’s stock valued at $116,000 after buying an additional 341 shares during the period. Bank of Montreal Can raised its position in shares of AxoGen by 978.5% in the first quarter. Bank of Montreal Can now owns 14,981 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 13,592 shares during the period. Menta Capital LLC raised its position in shares of AxoGen by 6.4% in the first quarter. Menta Capital LLC now owns 109,068 shares of the medical equipment provider’s stock valued at $1,140,000 after buying an additional 6,530 shares during the period. Finally, Summit Partners Public Asset Management LLC raised its position in shares of AxoGen by 27.4% in the first quarter. Summit Partners Public Asset Management LLC now owns 409,498 shares of the medical equipment provider’s stock valued at $4,279,000 after buying an additional 88,140 shares during the period. 63.49% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “AxoGen, Inc. (NASDAQ:AXGN) Given Average Rating of “Buy” by Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/07/25/axogen-inc-nasdaqaxgn-given-average-rating-of-buy-by-brokerages.html.

AxoGen (NASDAQ:AXGN) opened at 16.80 on Tuesday. The stock’s market capitalization is $556.00 million. The company’s 50-day moving average is $15.76 and its 200 day moving average is $12.43. AxoGen has a 1-year low of $6.45 and a 1-year high of $17.25.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Thursday, May 4th. The medical equipment provider reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The company had revenue of $12.24 million for the quarter, compared to analyst estimates of $11.83 million. AxoGen had a negative return on equity of 155.78% and a negative net margin of 32.05%. Equities analysts predict that AxoGen will post ($0.30) earnings per share for the current year.

About AxoGen

Analyst Recommendations for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.